Chapter 1. Introduction


1.1. Report description and scope

1.2. Research scope

1.3. Research methodology


1.3.1. Market research process

1.3.2. Market research methodology



Chapter 2. Executive Summary


2.1. Europe Precision Medicines market, 2014 - 2024 (USD Million)

2.2. Europe Precision Medicines market: Snapshot



Chapter 3. Europe Precision Medicines - Market Dynamics


3.1. Introduction

3.2. Market drivers


3.2.1. Increasing Technological advancement

3.3. Market Restraints


3.3.1. The high cost of treatment

3.4. Opportunities


3.4.1. Rising incidence of chronic diseases and growing outbreaks of epidemics

3.5. Porters five forces analysis


3.5.1. Bargaining power of suppliers

3.5.2. Bargaining power of buyers

3.5.3. The threat of new entrants

3.5.4. The threat of new substitutes

3.5.5. Degree of competition

3.6. Market attractiveness analysis


3.6.1. Market attractiveness analysis, by technology segment

3.6.2. Market attractiveness analysis, by End-users segment

3.6.3. Market attractiveness analysis, by application segment

3.6.4. Market attractiveness analysis, by regional segment



Chapter 4. Europe Precision Medicines market- Competitive Landscape


4.1. Company Market Share Analysis


4.1.1. Europe Precision Medicines market: company market share, 2014

4.2. Strategic Development


4.2.1. Acquisitions Mergers

4.2.2. New Therapy Launch

4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures

4.2.4. Research and Development, Therapy and Regional Expansion



Chapter 5. Europe Precision Medicines market- Technology Segment Analysis


5.1. Europe Precision Medicines market: Technology type overview


5.1.1. Europe Precision Medicines market revenue share, by technology, 2014 and 2024

5.2. Big Data Analytics


5.2.1. Europe Big Data Analytics market, 2014 - 2024(USD Million)

5.3. Bioinformatics


5.3.1. EuropeBioinformatics market, 2014 - 2024(USD Million)

5.4. Gene sequencing


5.4.1. Europe Gene sequencing market, 2014 - 2024(USD Million)

5.5. Drug Discovery


5.5.1. Europe Drug Discovery market, 2014 - 2024(USD Million)

5.6. Companion Diagnostic


5.6.1. Europe Companion Diagnostic market, 2014 - 2024(USD Million)

5.7. Others


5.7.1. Europe Others market , 2014 - 2024(USD Million)



Chapter 6. Europe Precision Medicines market- End-user Segment Analysis


6.1. Europe Precision Medicines market: End-user overview


6.1.1. Europe Precision Medicines market revenue share, by End-user, 2014- 2024

6.2. Diagnostic tool companies


6.2.1. Europe Precision Medicines market for Diagnostic tool companies, 2014 - 2024 (USD Million)

6.3. Healthcare IT/ Big data companies


6.3.1. Europe Precision Medicines market for Healthcare IT/ Big data companies,2014 - 2024 (USD Million)

6.4. Pharma Biotech companies


6.4.1. Europe Precision Medicines market for Pharma Biotech companies, 2014 - 2024 (USD Million)

6.5. Clinical Labs


6.5.1. Europe Precision Medicines market for Clinical Labs, 2014 - 2024 (USD Million)



Chapter 7. Europe Precision Medicines market- Application Segment Analysis


7.1. Europe Precision Medicines market: Application overview


7.1.1. Europe Precision Medicines market revenue share, by Application, 2014- 2024

7.2. Oncology


7.2.1. Europe Precision Medicines market for Oncology Application, 2014 - 2024 (USD Million)

7.3. CNS


7.3.1. Europe Precision Medicines market for CNS Application,2014 - 2024 (USD Million)

7.4. Immunology


7.4.1. Europe Precision Medicines market for Immunology Application, 2014 - 2024 (USD Million)

7.5. Respiratory


7.5.1. Europe Precision Medicines market for Respiratory Application, 2014 - 2024 (USD Million)

7.6. Others


7.6.1. Europe Precision Medicines market for Others Application, 2014 - 2024 (USD Million)



Chapter 8. Europe Precision Medicines market- Regional Segment Analysis


8.1. Europe Precision Medicines market: Regional overview


8.1.1. Europe Precision Medicines market revenue share, by region, 2014 and 2024

8.2. Germany


8.2.1. Germanyprecision medicines market revenue, by technology, 2014 - 2024 (USD Million)

8.2.2. Germanyprecision medicines market revenue, by end-users, 2014 - 2024 (USD Million)

8.2.3. Germanyprecision medicines market revenue, by applications, 2014 - 2024 (USD Million)

8.3. U.K


8.3.1. U.Kprecision medicines market revenue, by technology, 2014 - 2024 (USD Million)

8.3.2. U.Kprecision medicines market revenue, by end-users, 2014 - 2024 (USD Million)

8.3.3. U.Kprecision medicines market revenue, by applications, 2014 - 2024 (USD Million)

8.4. France


8.4.1. Franceprecision medicines market revenue, by technology, 2014 - 2024 (USD Million)

8.4.2. Franceprecision medicines market revenue, by end-users, 2014 - 2024 (USD Million)

8.4.3. Franceprecision medicines market revenue, by applications, 2014 - 2024 (USD Million)

8.5. Italy


8.5.1. Italyprecision medicines market revenue, by technology, 2014 - 2024 (USD Million)

8.5.2. Italyprecision medicines market revenue, by end-users, 2014 - 2024 (USD Million)

8.5.3. Italyprecision medicines market revenue, by applications, 2014 - 2024 (USD Million)

8.6. Spain


8.6.1. Spainprecision medicines market revenue, by technology, 2014 - 2024 (USD Million)

8.6.2. Spainprecision medicines market revenue, by end-users, 2014 - 2024 (USD Million)

8.6.3. Spainprecision medicines market revenue, by applications, 2014 - 2024 (USD Million)

8.7. Benelux


8.7.1. Beneluxprecision medicines market revenue, by technology, 2014 - 2024 (USD Million)

8.7.2. Beneluxprecision medicines market revenue, by end-users, 2014 - 2024 (USD Million)

8.7.3. Beneluxprecision medicines market revenue, by applications, 2014 - 2024 (USD Million)



Chapter 9. Company Profile


9.1. Roche


9.1.1. Overview

9.1.2. Financials

9.1.3. Therapy portfolio

9.1.4. Business strategy

9.1.5. Recent developments

9.2. QIAGEN N.V.


9.2.1. Overview

9.2.2. Financials

9.2.3. Therapy portfolio

9.2.4. Business strategy

9.2.5. Recent developments

9.3. Cepheid, Inc


9.3.1. Overview

9.3.2. Financials

9.3.3. Therapy portfolio

9.3.4. Business strategy

9.3.5. Recent developments

9.4. Johnson Johnson Services, Inc.


9.4.1. Overview

9.4.2. Financials

9.4.3. Therapy portfolio

9.4.4. Business strategy

9.4.5. Recent developments

9.5. Illumina


9.5.1. Overview

9.5.2. Financials

9.5.3. Therapy portfolio

9.5.4. Business strategy

9.5.5. Recent developments

9.6. Almac Group


9.6.1. Overview

9.6.2. Financials

9.6.3. Therapy portfolio

9.6.4. Business strategy

9.6.5. Recent developments

9.7. bioMrieux SA


9.7.1. Overview

9.7.2. Financials

9.7.3. Therapy portfolio

9.7.4. Business strategy

9.7.5. Recent developments

9.8. Intel Corporation


9.8.1. Overview

9.8.2. Financials

9.8.3. Therapy portfolio

9.8.4. Business strategy

9.8.5. Recent developments

9.9. GE Healthcare


9.9.1. Overview

9.9.2. Financials

9.9.3. Therapy portfolio

9.9.4. Business strategy

9.9.5. Recent developments

9.10. Novartis


9.10.1. Overview

9.10.2. Financials

9.10.3. Therapy portfolio

9.10.4. Business strategy

9.10.5. Recent developments

9.11. Thermo Fisher Scientific


9.11.1. Overview

9.11.2. Financials

9.11.3. Therapy portfolio

9.11.4. Business strategy

9.11.5. Recent developments